nach oben

Cardiovascular Toxicology

Erschienen in:

11.09.2017

The Effects of Periostin in a Rat Model of Isoproterenol: Mediated Cardiotoxicity

verfasst von: Mahmut Sözmen, Alparslan K. Devrim, Yonca B. Kabak, Tuba Devrim, Mert Sudagidan

Erschienen in: Cardiovascular Toxicology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Periostin is an extracellular matrix protein from fasciclin family, and it plays an important role in the cell adhesion, migration, and growth of the organism. Periostin prevents apoptosis while stimulating cardiomyocytes. The present study was designed to investigate cardioprotective effects of the recombinant murine periostin peptide administration in a rat model of isoproterenol (ISO)-induced myocardial injury. The experiment was performed on 84 adult male Sprague Dawley rats in 4 groups (n = 21): control group (1), periostin-treated group (2), ISO-treated group (3), and ISO + periostin-treated group (4). The groups were further divided into three subgroups based on the duration of the experiment in which rats were killed on days 1, 7, and 28 (n = 7). Growth factors (VEGF, ANGPT, FGF-2, TGFβ), mitosis and apoptosis (Bcl-2, Bax, PCNA, Ki-67, phospho-histone H3), cell cycle activators and inhibitors (cyclin D1, D2, A2, Cdc2), the origin of regenerating cells (cKit and CD45) mRNA were detected using quantitative real-time polymerase chain reaction (PCR) and PCR array. Immunohistochemistry staining was used to directly detect protein level and distribution in the heart tissues. Administration of periostin following ISO-induced cardiotoxicity revealed that periostin alleviated deleterious effects of ISO through several pathways: (1) periostin induced mitotic activity of endothelial/fibroblastic cells, (2) periostin drives cardiomyocytes into S and M phases, thus promoting proliferation of cardiomyocytes, (3) periostin contributed to collagen degradation, tissue remodeling, and reduced cardiac fibrosis during the healing process following myocardial damage while preserving tissue matrix, (4) periostin stimulated angiogenesis by upregulating THBS1, TGFB2, and HGF genes, (5) periostin regulated cell growth and proliferation while maintaining cell shape and cellular muscle contractions (ACTB) and functioned as chemoattractant factor (CCL2) at the beginning of myocardial damage.

Mathers, C. D., & Loncar, D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine, 3(11), e442.CrossRefPubMedPubMedCentral

Martin-Puig, S., et al. (2012). Heart repair: From natural mechanisms of cardiomyocyte production to the design of new cardiac therapies. Annals of the New York Academy of Sciences, 1254, 71–81.CrossRefPubMed

Piras, B. A., et al. (2016). Systemic injection of AAV9 carrying a periostin promoter targets gene expression to a myofibroblast-like lineage in mouse hearts after reperfused myocardial infarction. Gene Therapy, 23(5), 469–478.CrossRefPubMed

Engel, F. B., et al. (2005). p38 MAP kinase inhibition enables proliferation of adult mammalian cardiomyocytes. Genes & Development, 19(10), 1175–1187.CrossRef

Kuhn, B., et al. (2007). Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nature Medicine, 13(8), 962–969.CrossRefPubMed

Takeshita, S., et al. (1993). Osteoblast-specific factor 2: Cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochemical Journal, 294(Pt 1), 271–278.CrossRefPubMedPubMedCentral

Litvin, J., et al. (2006). Periostin and periostin-like factor in the human heart: Possible therapeutic targets. Cardiovascular Pathology, 15(1), 24–32.CrossRefPubMed

Stanton, L. W., et al. (2000). Altered patterns of gene expression in response to myocardial infarction. Circulation Research, 86(9), 939–945.CrossRefPubMed

Shimazaki, M., et al. (2008). Periostin is essential for cardiac healing after acute myocardial infarction. Journal of Experimental Medicine, 205(2), 295–303.CrossRefPubMedPubMedCentral

10.

Ojha, S., et al. (2013). Cardioprotective effect of lycopene against isoproterenol-induced myocardial infarction in rats. Human and Experimental Toxicology, 32(5), 492–503.CrossRefPubMed

11.

Oka, T., et al. (2007). Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circulation Research, 101(3), 313–321.CrossRefPubMedPubMedCentral

12.

Snider, P., et al. (2009). Origin of cardiac fibroblasts and the role of periostin. Circulation Research, 105(10), 934–947.CrossRefPubMedPubMedCentral

13.

Takeda, N., et al. (2010). Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. The Journal of Clinical Investigation, 120(1), 254–265.CrossRefPubMed

14.

Inagawa, K., & Ieda, M. (2013). Direct reprogramming of mouse fibroblasts into cardiac myocytes. Journal of Cardiovascular Translational Research, 6(1), 37–45.CrossRefPubMed

15.

Wei, Y., et al. (1998). Phosphorylation of histone H3 at serine 10 is correlated with chromosome condensation during mitosis and meiosis in Tetrahymena. Proceedings of the National Academy of the Science of the USA, 95(13), 7480–7484.

16.

Souders, C. A., et al. (2009). Cardiac fibroblast the renaissance cell. Circulation Research, 105(12), 1164–1176.CrossRefPubMedPubMedCentral

17.

Furtado, M. B., et al. (2014). Cardiogenic genes expressed in cardiac fibroblasts contribute to heart development and repair. Circulation Research, 114(9), 1422–1434.CrossRefPubMedPubMedCentral

18.

Zimmermann, R., et al. (1997). Time course of mitosis and collateral growth following coronary microembolization in the porcine heart. Cell and Tissue Research, 287(3), 583–590.CrossRefPubMed

19.

Yuasa, S., et al. (2004). Cardiomyocytes undergo cells division following myocardial infarction is a spatially and temporally restricted event in rats. Molecular and Cellular Biochemistry, 259(1–2), 177–181.CrossRefPubMed

20.

Tamamori-Adachi, M., et al. (2008). Cardiomyocyte proliferation and protection against post-myocardial infarction heart failure by cyclin D1 and skp2 ubiquitin ligase. Cardiovascular Research, 80(2), 181–190.CrossRefPubMed

21.

Du, W., & Pogoriler, J. (2006). Retinoblastoma family genes. Oncogene, 25(38), 5190–5200.CrossRefPubMedPubMedCentral

22.

Tamamori-Adachi, M., et al. (2008). Cardiomyocyte proliferation and protection against post-myocardial infarction heart failure by cyclin D1 and Skp2 ubiquitin ligase. Cardiovascular Research, 80(2), 181–190.CrossRefPubMed

23.

Pasumarthi, K. B., et al. (2005). Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice. Circulation Research, 96(1), 110–118.CrossRefPubMed

24.

Hassink, R. J., et al. (2008). Cardiomyocyte cell cycle activation improves cardiac function after myocardial infarction. Cardiovascular Research, 78(1), 18–25.CrossRefPubMed

25.

Busk, P. K., et al. (2005). Cyclin D2 induces proliferation of cardiac myocytes and represses hypertrophy. Experimental Cell Research, 304(1), 149–161.CrossRefPubMed

26.

Tamamori-Adachi, M., et al. (2008). Differential regulation of cyclin D1 and D2 in protecting against cardiomyocyte proliferation. Cell Cycle, 7(23), 3768–3774.CrossRefPubMed

27.

Tamamori-Adachi, M., et al. (2003). Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation. Circulation Research, 92(1), 12–19.CrossRef

28.

Diehl, J. A., et al. (1998). Glycogen synthase kinase-3beta regulates cyclin d1 proteolysis and subcellular localization. Genes & Development, 12(22), 3499–3511.CrossRef

29.

Deuse, T., et al. (2009). Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation, 120(11 Suppl), S247–S254.CrossRefPubMed

30.

Tuby, H., et al. (2006). Modulations of VEGF and iNOS in the rat heart by low level laser therapy are associated with cardioprotection and enhanced angiogenesis. Lasers in Surgery and Medicine, 38(7), 682–688.CrossRefPubMed

31.

Davis, S., et al. (1996). Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell, 87(7), 1161–1169.CrossRefPubMed

32.

Katsuragi, N., et al. (2004). Periostin as a novel factor responsible for ventricular dilation. Circulation, 110(13), 1806–1813.CrossRefPubMed

33.

Wang, D., et al. (2003). Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension, 42(1), 88–95.CrossRefPubMed

34.

Yoshioka, N., et al. (2002). Suppression of anchorage-independent growth of human cancer cell lines by the TRIF52/periostin/OSF-2 gene. Experimental Cell Research, 279(1), 91–99.CrossRefPubMed

35.

Taniyama, Y., et al. (2016). Selective blockade of periostin exon 17 preserves cardiac performance in acute myocardial infarction. Hypertension, 67(2), 356–361.PubMed

36.

Suzuki, G., et al. (2011). Autologous mesenchymal stem cells mobilize cKit + and CD133 + bone marrow progenitor cells and improve regional function in hibernating myocardium. Circulation Research, 109(9), 1044–1054.CrossRefPubMed

37.

Irigoyen, J. P., et al. (1999). The plasminogen activator system: Biology and regulation. Cellular and Molecular Life Sciences, 56(1–2), 104–132.CrossRefPubMed

38.

Stavropoulou, A., et al. (2010). uPA, uPAR and TGFβ₁ expression during early and late post myocardial infarction period in rat myocardium. In Vivo, 24(5), 647–652.PubMed

39.

Xia, Y., et al. (2011). Endogenous thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism. Hypertension, 58(5), 902–911.CrossRefPubMedPubMedCentral

40.

Nakamura, T., et al. (2000). Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. Journal of Clinical Investigation, 106(12), 1511–1519.CrossRefPubMedPubMedCentral

41.

Duan, H. F., et al. (2007). Adenoviral gene transfer of sphingosine kinase 1 protects heart against ischemia/reperfusion-induced injury and attenuates its postischemic failure. Human Gene Therapy, 18(11), 1119–1128.CrossRefPubMed

42.

Jianqiang, P., et al. (2015). Expression of hypoxia-inducible factor 1 alpha ameliorate myocardial ischemia in rat. Biochemical Biophysical Research Communications, 465(4), 691–695.CrossRefPubMed

43.

Arumugam, S., et al. (2012). Quercetin offers cardioprotection against progression of experimental autoimmune myocarditis by suppression of oxidative and endoplasmic reticulum stress via endothelin-1/MAPK signalling. Free Radical Research, 46(2), 154–163.CrossRefPubMed

44.

Doherty, G. J., & McMahon, H. T. (2008). Mediation, modulation, and consequences of membrane–cytoskeleton interactions. Annual Review of Biophysics, 37, 65–95.CrossRefPubMed

45.

Bujak, M., & Frangogiannis, N. G. (2007). The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovascular Research, 74(2), 184–195.CrossRefPubMed

46.

Schwarz, E. R., et al. (2004). Monocyte chemoattractant protein 1-induced monocyte infiltration produces angiogenesis but not arteriogenesis in chronically infarcted myocardium. Journal of Cardiovascular Pharmacolology Therapeutics, 9(4), 279–289.CrossRef

47.

Kakio, T., et al. (2000). Roles and relationship of macrophages and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the ischemic and reperfused rat heart. Laboratory Investigation, 80(7), 1127–1136.CrossRefPubMed

48.

Schaper, W. (2000). Quo vadis collateral blood flow? A commentary on a highly cited paper. Cardiovascular Research, 45(1), 220–223.CrossRefPubMed

49.

Lee, S. G., et al. (2012). Effect of lipoic acid on expression of angiogenic factors in diabetic rat retina. Clinical and Experimental Ophthalmology, 40(1), e47–e57.CrossRefPubMed

50.

Cao, H., et al. (2006). Novel role for stat-5b in the regulation of hsp27-fgf-2 axis facilitating thrombin-induced vascular smooth muscle cell growth and motility. Circulation Research, 98(7), 913–922.CrossRefPubMed

51.

Bian, Y., et al. (2009). Neuregulin-1 attenuated doxorubicin-induced decrease in cardiac troponins. American Journal of Physiology Heart and Circulatory Physiology, 297(6), H1974–H1983.CrossRefPubMedPubMedCentral

52.

Thompson, K. L., et al. (2010). Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemotherapy and Pharmacology, 66(2), 303–314.CrossRefPubMed

53.

Fukuda, K., et al. (2001). Quantification of TGF-beta1 mRNA along rat nephron in obstructive nephropathy. American Journal of Physiology. Renal Physiology, 281(3), F513–F521.CrossRefPubMed

54.

McFee, R. M., et al. (2009). Inhibition of vascular endothelial growth factor receptor signal transduction blocks follicle progression but does not necessarily disrupt vascular development in perinatal rat ovaries. Biology of Reproduction, 81(5), 966–977.CrossRefPubMedPubMedCentral

55.

Mikalsen, B., et al. (2010). Genome-wide transcription profile of endothelial cells after cardiac transplantation in the rat. American Journal of Transplantation, 10(7), 1534–1544.CrossRefPubMed

Titel: The Effects of Periostin in a Rat Model of Isoproterenol: Mediated Cardiotoxicity
verfasst von: Mahmut Sözmen
Alparslan K. Devrim
Yonca B. Kabak
Tuba Devrim
Mert Sudagidan
Publikationsdatum: 11.09.2017
Verlag: Springer US
Erschienen in: Cardiovascular Toxicology / Ausgabe 2/2018
Print ISSN: 1530-7905
Elektronische ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-017-9426-y

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Quercetin Reverses Altered Energy Metabolism in the Heart of Rats Receiving Adriamycin Chemotherapy

A Case of Severe, Refractory Hypotension After Amlodipine Overdose

Asiatic Acid Ameliorates Doxorubicin-Induced Cardiac and Hepato-Renal Toxicities with Nrf2 Transcriptional Factor Activation in Rats

Diosmin Prevents Isoproterenol-Induced Heart Mitochondrial Oxidative Stress in Rats

Xanthine Oxidase Activation Modulates the Endothelial (Vascular) Dysfunction Related to HgCl2 Exposure Plus Myocardial Infarction in Rats

Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors